Please login to the form below
European Society of Cardiology
This page shows the latest European Society of Cardiology news and features for those working in and with pharma, biotech and healthcare.
AZ’s Farxiga cuts risk of death in chronic kidney disease
Detailed results revealed at the European Society of Cardiology virtual congress. ... AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of
Latest news
-
AstraZeneca’s heart failure drug Farxiga scores FDA priority review
broad diabetes patient population, most of whom had no cardiovascular disease at enrolment, compared with placebo. ... AstraZeneca’s HFrEF trial of Farxiga – named DAPA-HF – was hailed as a ‘landmark trial’ when it was presented at last
-
AZ’s Farxiga gets heart failure prevention okay from FDA
attack or stroke,” said Ruud Dobber, executive vice president of biopharmaceuticals at AZ. ... The HFrEF trial, called DAPA-HF, was presented at this year’s European Society of Cardiology (ESC) congress in Paris to some fanfare, showing that
-
TMC preps filings for inclisiran after final phase 3 trials hit the mark
burden. ORION-10 involved patients with atherosclerotic cardiovascular disease (ASCVD), and the results back up the earlier ORION-11 data in the same patient population which was presented at the European ... Society of Cardiology (ESC) congress
-
FDA fast-tracks AstraZeneca’s Farxiga in heart failure
Earlier this month, AZ revealed the results of the DAPA-HF trial of its diabetes therapy Farxiga, to an eager crowd at the European Society of Cardiology. ... This hard-to-treat form of the disease currently has no approved drug therapies.
-
AZ’s Farxiga heart failure results wow the ESC
Lead investigator John McMurray of the University of Glasgow presented the results at the European Society of Cardiology (ESC) congress in Paris over the weekend to an enthusiastic audience. ... non-diabetic population and make it an option for the
AstraZeneca’s heart failure drug Farxiga scores FDA priority review
TMC preps filings for inclisiran after final phase 3 trials hit the mark
AZ’s Farxiga heart failure results wow the ESC
More from news
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
Is it possible to change behaviour virtually?
One of my colleagues, Emma, has also incorporated virtual technology into a medical education programme. ... What value did the virtual mannequin add? . It was the first time ever a virtual mannequin had been used at the European Society of Cardiology
-
Helping European cardiologists keep up to date
But when asked about their propensity to take part in programmes in relation to: (1) the sponsoring organisation (independent bodies such as the European Society of Cardiology or an unrestricted grant ... Figure 4: EU5 average of preferences of online
-
Change drivers: multi-stakeholder education and collaboration
Professor John Camm, Chair of the European Society of Cardiology Committee for Guidelines on the Management of Atrial Fibrillation told me recently: “Well-meaning rewording of key messages to 'suit' different ... It resulted in improved cholesterol
-
Closing the treatment gap
Timescale:March 2009 to August 2009. The annual European Society of Cardiology Congress is the largest global cardiology meeting, attracting thousands of delegates and hundreds of journalists; the competition between pharmaceutical ... Merck, with a
-
A very favourable verdict
Timescale:July 2009 to December 2009. Guest delegates of DAIICHI SANKYO UK at the European Society of Cardiology Congress were subpoenaed to appear on a jury at The Formulary Court of ... meetings and will also roll out via a series of regional GP
Is it possible to change behaviour virtually?
Helping European cardiologists keep up to date
Change drivers: multi-stakeholder education and collaboration
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Conference research case study
Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. ... meant to our clients key customers and the overall impact of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Events Executive
-
Depending on Experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
